Key positives include a clearly defined scientific focus on neuroinflammation, a differentiated intranasal delivery technology, and a lead asset with potential applications across several serious diseases. The company has improved its cost structure, reduced its operating losses and cash burn, and kept traditional debt low, which limits interest burden. Its patent portfolio and specialist manufacturing partnerships add structure and credibility to the development plan.

Major risks center on the absence of revenue, persistent though smaller losses, and a sharply weakened balance sheet with much lower cash and equity than in prior years. The business model depends on successful clinical outcomes and continued access to external capital; setbacks on either front could quickly constrain operations. Competition in neurodegenerative and inflammatory diseases is intense, regulatory pathways are uncertain, and reduced R&D spending may slow progress or limit the breadth of the pipeline.

Looking ahead, the company’s trajectory will be driven mainly by clinical milestones for foralumab, its ability to manage cash carefully, and its success in raising additional funds or forming partnerships. Operationally, trends in losses and cash burn have improved, but financial flexibility is now limited after years of asset drawdown. The outlook is inherently high risk and highly dependent on scientific and regulatory outcomes: meaningful upside exists if trials are successful and financing remains available, but the path involves substantial uncertainty and execution challenges typical of small clinical‑stage biotechs.